Clinical Trial

A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 8, 2024 (before its estimated April 25, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase Ia/Ib, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, pharmacodynamics (PD) and preliminary efficacy of GH2616 Tablet in subjects with advanced solid tumors. It includes two parts: the dose escalation study (Phase Ia) and the dose expansion study (Phase Ib).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-03-18; most recent amendment 2024-07-03.
Status change: Not Yet Recruiting → Recruiting 2024-04-01
Trial Details
NCT Number NCT06329206
Lead Sponsor Suzhou Genhouse Bio Co., Ltd.
Collaborators: Zhejiang Cancer Hospital, Henan Cancer Hospital, Hubei Cancer Hospital, The First Affiliated Hospital of Zhengzhou University
Conditions Advanced Solid Tumors
Enrollment 156 participants
Start Date 2024-03-20
Primary Completion 2026-04-25 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2024-07-08